Belladonna Tincture and Oxymetazoline Hydrochloride

• Generic Name: belladonna
• Dosage Forms: n.a.
• Other Brand Names: Belladonna Tincture, Belladonna Leaf

Belladonna Tincture is a plant also known as Atropa Belladonna Tincture, Atropa acuminata, Baccifère, Belle-Dame, Belle-Galante, Bouton Noir, Cerise du Diable, Deadly Nightshade, Devil's Cherries, Devil's Herb, Divale, Dwale, Dwayberry, Grande Morelle, Guigne de la Côte, Herbe à la Mort, Herbe du Diable, Morelle Furieuse, Naughty Man's Cherries, Poison Black Cherries, Suchi, and other names.

Belladonna Tincture has been used in alternative medicine as an aid in treating arthritis pain, colds or hay fever, bronchospasms caused by asthma or whooping cough, hemorrhoids, nerve problems, Parkinson's disease, colic, irritable bowel syndrome, and motion sickness.

It is not certain whether Belladonna Tincture is effective in treating any medical condition, and Belladonna Tincture can be toxic. Medicinal use of this product has not been approved by the FDA. Belladonna Tincture should not be used in place of medication prescribed for you by your doctor.

Belladonna Tincture is often sold as an herbal supplement. There are no regulated manufacturing standards in place for many herbal compounds and some marketed supplements have been found to be contaminated with toxic metals or other drugs. Herbal/health supplements should be purchased from a reliable source to minimize the risk of contamination.

Belladonna Tincture may also be used for purposes not listed in this product guide.

• Generic Name: oxymetazoline ophthalmic
• Dosage Forms: n.a.
• Other Brand Names: Visine LR, Visine Long Lasting, Ocuclear

Self-medication for temporary relief of nasal congestion associated with the common cold, hay fever, or other upper respiratory allergies.

As effective as other topical vasoconstrictors.

Labeled and has been used for self-medication for temporary relief of nasal congestion associated with sinusitis; however, efficacy data are lacking and/or controversial. In October 2005, FDA issued final rule to remove this indication from labeling of OTC nasal decongestants. Compliance date for preparations with annual sales <$25,000 is October 11, 2007; compliance date for all other preparations is April 11, 2007.

Self-medication for temporary relief of ocular redness due to minor irritation.

Has been used for self-medication for symptomatic prevention of otitic barotrauma (aerotitis [barotitis] media); however, no more effective than placebo.